ANNA KRAVTSOV: Open Payments
NPI 1114243805 · WAYNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$537 in 26 payments from 10 companies in 2025. Trend: 2023 $111 · 2024 $708 · 2025 $537
Food & beverage: $537
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $129 |
| Otsuka America Pharmaceutical, Inc. | 5 | $82 |
| Teva Pharmaceuticals USA, Inc. | 5 | $81 |
| Alkermes, Inc. | 4 | $67 |
| ABBVIE INC. | 4 | $59 |
| Neurocrine BioSciences, Inc. | 3 | $54 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
Products named: CAPLYTA, REXULTI, UZEDY, VRAYLAR, INGREZZA, ARISTADA, FANAPT, TRINTELLIX.
Industry payments across NJ — which companies pay providers there.
